Indications
Pick a disease — see who leads and whether cash covers the next gate.
Gene therapy, exon skipping, and cell therapies racing toward broader DMD labels.
Anti-amyloid, anti-tau, and next-gen disease modifiers after the first wave of approvals.
Incretin and next-wave oral/combination approaches competing on efficacy, tolerability, and access.
EGFR TKIs, PD-1/VEGF bispecifics, and RAS(ON) inhibitors competing in lung cancer.
Gene editing and gene therapy platforms expanding beyond first commercial launches.
BTK inhibitors and next-gen remyelination approaches after anti-CD20 dominance.
Post-Rezdiffra field: FGF21s, GLP-1 combos, and fibrosis-focused assets.
Factor mimetics, gene therapy durability, and rebalancing agents.
Antibody-drug conjugates competing across HER2-low, HER2+, and TROP2 breast segments.
Radioligands, T-cell engagers, and next-gen hormone/PARP combinations in metastatic castration-resistant disease.
CAR-T, bispecifics, and CD38 franchises racing across earlier lines of therapy.
IO in MSI-H, RAS-targeted agents, and ADCs reshaping metastatic CRC.
In vivo editing platforms racing from liver-targeted rare diseases outward.